Concord Biotech Ltd
Concord Biotech Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.
From Concord Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%.
- There is good visibility for growth starting from Q1 and Q2 of FY27.
- The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid).
- Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex.
- The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores.
- Growth levers include new injectables facility, U.S. subsidiary Stellon Biotech, CDMO opportunities, and topical range facility.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects.
- No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year.
- Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project.
- Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Concord Biotech has significant visibility on the orderbook for the first half of FY27.
- Inventory levels are slightly elevated but mostly linked to identified customer demand or forecasts, especially outside the Middle East.
- In the Middle East, inventory is primarily API-related due to staggered approaches caused by geopolitical challenges; formulation inventory is not held due to shelf life issues.
- Some tenders, especially in the Middle East formulations, were delayed in FY26 but remain work in progress.
- The timing issues in tender execution affected FY26 but are expected to normalize with gradual supplies in FY27.
2 more points management made on order book & pipeline
Concord Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹278 Cr, net profit ₹68 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Concord Biotech Ltd Q4 FY26 results?
Concord Biotech expects strong revenue growth in FY27, likely exceeding their historical growth rate of around 18%. - There is good visibility for growth starting from Q1 and Q2 of FY27. - The company anticipates volume growth in APIs, particularly in anti-infective and oncology segments, driven by new product launches (e.g., Nystatin, Fusidic Acid). - Capacity utilization is progressively improving with Unit 1 at optimal capacity and Unit 3 around 50%, supporting growth without immediate large capex. - The manufacturing capacities across units can support peak revenue potential of approximately INR 3,000 crores. - Growth levers include new injectables facility, U.S. Concord Biotech expects strong growth in FY27, with visibility for growth starting from Q1 and Q2. - Historical growth rate around 18%; FY27 growth is expected to be slightly better than this. - Operating leverage from injectables and Stellon Biotech U.S.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Is Concord Biotech Ltd planning capital expenditure?
Current year capex guidance is around INR 20-30 crores, mainly for maintenance and smaller growth projects. - No large capex expected this year unless new projects require it, e.g., additional facility for topical range planned this financial year. - Recently commissioned facilities include soft gel facility and injectable plant; some capex spent on modifications for a large-volume innovator project. - Next substantial capex tranche (above INR 50-100 crores) likely 2-3 years out, with any very large additions 4-5 years away. - Existing capacities are adequate to support turnover up to INR 3,000 crores; future capex mostly for debottlenecking/maintenance or new customer-driven projects. - Strategic growth levers include expansion in injectables, CDMO through Stellon Biotech (U.S.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.